Danske Bank’s Sarepta Therapeutics SRPT Stock Holding History

Danske Bank’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8K	Hold	100	–	–	﹤0.01%	993
2026 Q1	$2.18K	Sell	100 -100	-50%	-$1.94K	﹤0.01%	989
2025 Q4	$4.3K	Hold	200	–	–	﹤0.01%	1371
2025 Q3	$3.85K	Sell	200 -777	-80%	-$13.9K	﹤0.01%	1334
2025 Q2	$16.7K	Sell	977 -20,955	-96%	-$894K	﹤0.01%	1215
2025 Q1	$1.4M	Buy	21,932 +1,935	+10%	+$204K	﹤0.01%	767
2024 Q4	$2.43M	Buy	19,997 +5,516	+38%	+$676K	0.01%	612
2024 Q3	$1.81M	Buy	14,481 +2,472	+21%	+$342K	0.01%	674
2024 Q2	$1.9M	Sell	12,009 -10,641	-47%	-$1.37M	0.01%	631
2024 Q1	$2.93M	Buy	+22,650	New	+$2.77M	0.01%	633

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Danske Bank's SRPT Position: Q2 2026 in Review

Danske Bank held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 100 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Danske Bank first reported a position in SRPT in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.93M in Q1 2024. 235 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Danske Bank held 100 shares of Sarepta Therapeutics worth $1.8K as of Q2 2026.
Danske Bank left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #993 holding.
Danske Bank first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 10 quarters since.
Danske Bank's Sarepta Therapeutics position peaked at $2.93M in Q1 2024.
235 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.